Shares of Transenterix Inc (NYSEAMERICAN:TRXC) gapped down prior to trading on Thursday . The stock had previously closed at $2.32, but opened at $2.27. Transenterix shares last traded at $2.22, with a volume of 2119700 shares changing hands.
TRXC has been the subject of a number of research analyst reports. Stifel Nicolaus increased their target price on Transenterix from $3.75 to $4.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Ladenburg Thalmann Financial Services set a $5.00 target price on Transenterix and gave the company a “buy” rating in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.61.
In other news, CFO Joseph P. Slattery sold 529,609 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $2.80, for a total value of $1,482,905.20. Following the sale, the chief financial officer now directly owns 440,974 shares of the company’s stock, valued at $1,234,727.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the sale, the insider now directly owns 462,644 shares in the company, valued at $1,702,529.92. The disclosure for this sale can be found here. Insiders have sold 1,462,609 shares of company stock worth $4,666,595 over the last three months.
ILLEGAL ACTIVITY NOTICE: “Transenterix (TRXC) Shares Gap Down to $2.27” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/12/07/transenterix-trxc-shares-gap-down-to-2-27.html.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.